CDA | Evidence Driven
CDA | Evidence Driven

dulaglutide

Details

Files
Generic Name:
dulaglutide
Project Status:
Complete
Therapeutic Area:
Diabetes mellitus, Type 2
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Trulicity
Project Line:
Reimbursement Review
Project Number:
SR0462-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Submission Type:
Initial
Indications:
Diabetes mellitus, Type 2
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:

Files

Recommandation et motifs : Rapport mise à jour View PDF
Submission Status Report View PDF
Recommendation and Reasons: Original View PDF
Clinical Report View PDF
Pharmacoeconomic Report View PDF
Patient Group Input Submissions View PDF
Last Updated : March 22, 2024